We then used Kaplan Meier survival analysis of patients’ RFS and found that PD-L1 co-expression with NFKB2 (p < 0.001) (Fig. 3C) and also with CA9 expression; a hypoxic biomarker significantly predicted tumor progression in our cohort (p = 0.001, Fig. 3D) (Table 4). The gene discussed is NFKB2; the disease is neoplasm.